FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
0.9500
-0.0700 (-6.86%)
At close: Mar 28, 2025, 4:00 PM
1.016
+0.066 (6.98%)
After-hours: Mar 28, 2025, 7:55 PM EDT
Company Description
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company.
It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.
It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
FibroBiologics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 31, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Peter O’Heeron |
Contact Details
Address: 455 East Medical Center Boulevard, Suite 300 Houston, Texas 77598 United States | |
| Phone | 281 651 5150 |
| Website | fibrobiologics.com |
Stock Details
| Ticker Symbol | FBLG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $30.00 |
| CIK Code | 0001958777 |
| CUSIP Number | 31573L105 |
| ISIN Number | US31573L1052 |
| Employer ID | 86-3329066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter O'Heeron | Founder, Chairperson and Chief Executive Officer |
| Robert E. Hoffman B.B.A., CPA | Interim Chief Financial Officer and Director |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Ruben A. Garcia J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 10, 2025 | EFFECT | Notice of Effectiveness |
| Feb 7, 2025 | 8-K | Current Report |
| Feb 6, 2025 | UPLOAD | Filing |
| Feb 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 30, 2025 | SCHEDULE 13G/A | Filing |
| Jan 29, 2025 | SCHEDULE 13G | Filing |
| Jan 24, 2025 | 8-K | Current Report |
| Jan 21, 2025 | EFFECT | Notice of Effectiveness |
| Jan 17, 2025 | POS AM | Post-Effective amendments for registration statement |